DAVIS ROBERT T. JR. 4

What Happened Robert T. Davis Jr., EVP & President of Integra Lifesciences (IART), was granted 43,350 restricted stock units (RSUs) on 2026-03-11. To cover tax obligations related to the award, a total of 9,174 shares were withheld/disposed: 687 shares on 2026-03-10 at $9.55 (≈ $6,561) and 8,487 shares on 2026-03-11 at $9.61 (≈ $81,560), for combined proceeds of about $88,121. The award itself is recorded as a derivative grant with no cash purchase.

Key Details

• Transactions:
  • 2026-03-10: 687 shares withheld/disposed @ $9.55 = $6,561 (Code F: tax withholding)
  • 2026-03-11: 8,487 shares withheld/disposed @ $9.61 = $81,560 (Code F)
  • 2026-03-11: Grant of 43,350 RSUs @ $0.00 (Code A: award/derivative)
• Total withheld/disposed shares: 9,174; total value ≈ $88,121.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnote: The RSU award vests 33% on the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.
• Filing timeliness: Report filed 2026-03-12; appears to be filed on time (Form 4 is generally due within two business days).

Context

• The grant is an RSU award (not an open-market purchase). RSUs are a form of compensation that convert to shares when they vest; this grant will vest over three years per the footnote.
• The small dispositions were tax-withholding actions (Code F), a routine administrative step when awards are granted or vested; these are not the same as an open-market sale and do not necessarily indicate a change in the insider’s market view.
• For retail investors, new RSU grants signal compensation alignment with shareholders but are common for executives and don't alone imply buying or selling sentiment.